Viyash Life Sciences

About

• Industry: Pharmaceutical Manufacturing
• Company: Private
• Number of Employees: 2,500
• Headquarter: Hyderabad, India
• Global Presence: 150+ Countries
• ESG Needs: GRI, GHG (Scope 1, 2, 3), Materiality assessment, EcoVadis, Supply Chain Sustainability, ESG Data Management Platform

Company Overview

Viyash Life Sciences is a global leader in the pharmaceutical industry, specializing in the production of Active Pharmaceutical Ingredients (APIs) and formulations across 150+ countries. With a robust operational footprint spanning eight manufacturing plants and a corporate headquarters, the company plays a critical role in advancing healthcare solutions worldwide.

Committed to sustainable growth and operational excellence, Viyash Life Sciences integrates Environmental, Social, and Governance (ESG) principles into its core business strategy. By aligning with international sustainability standards, the company aims to enhance stakeholder trust, drive responsible procurement, and contribute to a more sustainable pharmaceutical industry.

Project Overview

As part of its commitment to continuous ESG improvement, Viyash Life Sciences partnered with Oren to implement a comprehensive sustainability strategy. The collaboration focused on materiality assessment, greenhouse gas (GHG) accounting, GRI-aligned reporting, supply chain sustainability, and EcoVadis score enhancement—key components essential for strengthening the company’s ESG performance.

Oren provided end-to-end ESG support, facilitating stakeholder engagement, GHG emissions and ESG data collection, and EcoVadis assessment. Additionally, the project involved close collaboration with Viyash’s top suppliers to drive responsible procurement practices and elevate overall sustainability performance.

Key Challenges

• Materiality Assessment & Stakeholder Engagement: Viyash Life Sciences needed a structured materiality assessment to pinpoint the most critical sustainability topics and align with stakeholder expectations within India's API and formulation sectors.
• Comprehensive GHG Accounting: With operations spread across multiple locations, the company required precise data collection and analysis to measure carbon emissions across Scope 1, 2, and 3 categories.
• Supply Chain Sustainability: To drive ESG improvements beyond its own operations, Viyash sought to assess and elevate the sustainability performance of its top 30+ suppliers through targeted engagement and structured feedback mechanisms.
• EcoVadis Score Improvement: Viyash aimed to enhance its standing across all four EcoVadis assessment themes, with a particular focus on responsible procurement, ensuring alignment with global sustainability benchmarks.

Oren’s Solutions

To address these challenges, Oren implemented a structured, data-driven approach tailored to Viyash Life Sciences' sustainability objectives:

• Materiality Assessment & Stakeholder Engagement: Oren conducted a comprehensive materiality assessment, identifying priority sustainability topics for the pharmaceutical sector. By engaging both internal and external stakeholders, the process ensured alignment with global ESG standards.
• Scope 1, 2, and 3 Emissions Management: Leading data collection across 9 locations (8 manufacturing plants and 1 corporate office), Oren calculated Scope 1, 2, and 3 emissions. Using a spend-based methodology, the team provided clarity on the most relevant Scope 3 categories, enabling targeted reduction strategies.
• GRI-Aligned Reporting: To enhance transparency and regulatory compliance, Oren developed a comprehensive sustainability report aligned with Global Reporting Initiative (GRI) standards, ensuring accurate and globally recognized disclosures.
• Supply Chain Sustainability Engagement: Through the Oren Sustainability Hub, Oren engaged with Viyash Life Sciences' top 30+ suppliers, gathering feedback and implementing structured improvement initiatives. Suppliers were categorized into red, amber, and green tiers, with targeted action plans to elevate ESG performance.
• EcoVadis Score Enhancement: Oren collaborated closely with Viyash Life Sciences to enhance its EcoVadis performance across all four assessment themes, achieving a twofold increase in the company’s responsible procurement score.

Key Outcomes

• Successful GRI Report Development: Viyash Life Sciences successfully published a comprehensive sustainability report aligned with Global Reporting Initiative (GRI) standards, reinforcing its commitment to transparency and best practices in ESG reporting.
• Enhanced Emissions Management: Leveraging Oren’s structured approach to Scope 1, 2, and 3 emissions reporting, Viyash Life Sciences gained actionable insights into its environmental footprint, enabling more effective emissions reduction strategies.
• Improved Supply Chain Sustainability: Through targeted supplier engagement and performance tracking, Viyash Life Sciences enhanced the sustainability of its supply chain, driving measurable ESG improvements across its top suppliers.
• EcoVadis Score Improvement: Focused efforts on responsible procurement and ESG strategy led to a substantial improvement in Viyash Life Sciences’ EcoVadis rating, strengthening its reputation as a sustainability leader in the pharmaceutical industry.

Through its collaboration with Oren, Viyash Life Sciences has made measurable progress in embedding sustainability into its core operations. By implementing structured stakeholder engagement, rigorous reporting, and supply chain optimization, the company is well-positioned for long-term ESG leadership and continued growth in the pharmaceutical sector.